Published 1 month ago • loading... • Updated 1 month ago

FDA Ends Semaglutide Shortage Listing, Contributing to Ongoing Legal Challenges

Summary by Pharmacy Times

Pharmacies could still experience localized availability issues for semaglutide despite its removal from the drug shortage list.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

mric-global

Boston Wellness News Part 2: A surprising number of people stop taking popular weight loss drugs (3/3)

Mutsuko Ohnishi, MD, Internal medicine physician in Boston, USA Continuing from the previous article, today’s topic is also about the much-talked-about weight-loss drugs. In the U.S., Novo Nordisk’s obesity treatment drug Semaglutide (brand name: Wegovy), the type 2 diabetes treatment drug with weight-loss effects Semaglutide (brand name: Ozempic, with a lower dose of Semaglutide than Wegovy), and Eli Lilly’s type 2 diabetes treatment drug with …

1 month ago

Read Full Article

cardiovascularbusiness.com

FDA sued over ‘reckless and arbitrary’ semaglutide decision

The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.

1 month ago

Read Full Article